| Name | Kallikrein-1 | ||
| UniProt ID | KLK1_HUMAN | ||
| Gene Name | KLK1 | ||
| Gene ID | 3816 | ||
| Synonyms |
KLK1, KLKR, Klk6, hK1
|
||
| Sequence |
MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWV
LTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHD LMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKIL PNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNK PSVAVRVLSYVKWIEDTIAENS |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa3816 | ||
| TTD ID | T40000 | ||
| Pfam | PF00089; PF09342; PF13365 | ||
| Pair Name | Acteoside, Sorafenib | |||
| Phytochemical | Acteoside | |||
| Drug | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Regulate Info | Down-regulation | Kallikrein-1 | Expression | |
| Result | Acteoside exerts an antitumor effect possibly through its up-regulation of p53 levels as well as inhibition of KLK expression and angiogenesis. Acteoside could be useful as an adjunct in the treatment of advanced HCC in the clinic. | |||
